Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially transformational acquisitions. As we look towards the earnings report next week, we ...

Analysts raise price forecasts. Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio Lantheus strengthens its radiopharmaceutical ...

Lantheus aims to close acquisitions of Life Molecular Imaging and Evergreen Theranostics to bolster growth. The company plans to launch new assets, including MK 6,240, NAV 4,694, Octavie ...

In January, Lantheus Holdings (NASDAQ:LNTH) signed a definitive agreement to acquire Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, in an all-cash deal. The agreement ...

The acquisition of Evergreen Theragnostics will enhance the Company's position as an end-to-end fully integrated radiopharmaceutical leader, expanding manufacturing and R&D capabilities. The ...

Lantheus aims to close acquisitions of Life Molecular Imaging and Evergreen Theranostics to bolster growth. The company plans to launch new assets, including MK 6,240, NAV 4,694, Octavie, and PNT 2003 ...